rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Jason B. Daly

EVP, Chief Legal Officer

Company insider

Files Form 4 as: EVP, Chief Legal Officer, Amneal Pharmaceuticals.

In numbers

Trades disclosed
72
Buys
0
Sells
7
Bought
$0
Sold
$9.0M
Companies
1
Companies where not an officer
0
First trade
3 Mar 2022
Last trade
12 Aug 2026
Last filed
13 Aug 2026

Companies traded

Where they are an officer
AMRX Amneal PharmaceuticalsOfficer · Pharmaceuticals · last 12 Aug 20260 buys · 7 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
12 Aug 2026filed 13 Aug 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Sold$3.7M210,000 at $17.40filing
12 Aug 2026filed 13 Aug 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Sold$3.7M210,000 at $17.40filing
11 Aug 2026filed 13 Aug 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Sold$117K6,613 at $17.70filing
11 Aug 2026filed 13 Aug 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Sold$117K6,613 at $17.70filing
4 Mar 2026filed 5 Mar 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Code F$207K15,580 at $13.30filing
4 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—35,880 at $0.00filing
4 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—35,880 at $0.00filing
4 Mar 2026filed 5 Mar 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Code M—35,880filing
4 Mar 2026filed 5 Mar 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Code F$207K15,580 at $13.30filing
4 Mar 2026filed 5 Mar 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Code M—35,880filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Code M—22,645filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—22,645 at $0.00filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—38,226 at $0.00filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—24,258 at $0.00filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—305,810 at $0.00filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Code F$135K10,147 at $13.31filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal PharmaceuticalsPharmaceuticalsSEC FORM 4 Code M—38,226filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—22,645 at $0.00filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—38,226 at $0.00filing
3 Mar 2026filed 5 Mar 2026AMRX Amneal Pharmaceuticalsoption or derivative · PharmaceuticalsSEC FORM 4 Code M—24,258 at $0.00filing

News

Head to Head Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) & NRx Pharmaceuticals (NASDAQ:NRXP)AMRX · themarketsdaily.com · 18 Oct 2026

0 headlines in the last 90 days name Jason B. Daly; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care7

Buys in green, sells in red, by the company’s sector.

Related people

J. Kevin BuchiDirector · Director at Amneal Pharmaceuticals, filing Form 4 there in the last year
Andrew S. BoyerExecutive Vice President · Executive Vice President at Amneal Pharmaceuticals, filing Form 4 there in the last year
John KielyDirector · Director at Amneal Pharmaceuticals, filing Form 4 there in the last year
Nikita ShahExecutive Vice President · Executive Vice President at Amneal Pharmaceuticals, filing Form 4 there in the last year
Gautam PatelDirector · Director at Amneal Pharmaceuticals, filing Form 4 there in the last year